Search Results 3751-3760 of 26503 for oral

  1. Marie F. Grill, M.D. - Doctors and Medical Staff - Mayo Clinic

    Third Place Oral PresentationAcademic Excellence Day, St. Joseph's Hospital and Medical Center. 2009. Resident Symposium ScholarshipAmerican Neurological ...

  2. Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age (PrE0405) - Mayo Clinic

    Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is ...

  3. How safe and effective are new drugs for stroke prevention? - Mayo Clinic News Network

    — For decades, warfarin was the only oral blood thinner available to reduce the risk of stroke for patients with atrial fibrillation. Warfarin use is ...

  4. William E. Krauss, M.D. - Doctors and Medical Staff - Mayo Clinic

    Awards and honors · 2011. AwardeeWho's Who in Medicine and Health Care · 2011. Guest Examiner Oral BoardsAmerican Board of Neurological Surgery · 2010. Awardee ...

  5. Alcoholic Hepatitis Clinical Trials - Mayo Clinic Research

    Hypothesis: Oral administration of hyperimmune bovine colostrum enriched with anti-LPS antibodies will reduce endotoxemia, and improve pathophysiological ...

  6. Joaquin Sanchez-Sotelo, M.D., Ph.D. - Doctors and Medical Staff - Mayo Clinic

    2019 First Award for Oral Presentation at 20th General Meeting ISOLS 2019 for "Comparison of Reconstructive Techniques Following Oncologic Intraarticular ...

  7. A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease - Mayo Clinic

    * Any ongoing treatment with systemic immunosuppressants, systemic corticosteroids, or use of oral budesonide in the 12 weeks before screening. * Ongoing ...

  8. Olaparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer - Mayo Clinic

    ... oral calcineurin inhibitors; high potency or oral steroids) 3.2.10 History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced) ...

  9. Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy - Mayo Clinic

    Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is ...

  10. Head and neck cancers - Doctors and departments - Mayo Clinic

    Oral and Maxillofacial Surgery · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology/Oncology · Pediatric Otolaryngology · Pediatrics · Physical ...